{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T02:26:24Z","timestamp":1793067984325,"version":"4.5.0"},"reference-count":218,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008308","name":"Comprehensive Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008308","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004381","name":"Western","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004381","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008235","name":"School of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008235","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008308","name":"Comprehensive Cancer Center","doi-asserted-by":"publisher","award":["P30 CA043703"],"award-info":[{"award-number":["P30 CA043703"]}],"id":[{"id":"10.13039\/100008308","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thegreenjournal.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.radonc.2017.09.043","type":"journal-article","created":{"date-parts":[[2017,10,19]],"date-time":"2017-10-19T04:18:42Z","timestamp":1508386722000},"page":"450-464","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":343,"title":["ATR\/CHK1 inhibitors and cancer therapy"],"prefix":"10.1016","volume":"126","author":[{"given":"Zhaojun","family":"Qiu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy L.","family":"Oleinick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junran","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2017.09.043_b0005","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/nrc3399","article-title":"DNA repair dysregulation from cancer driver to therapeutic target","volume":"12","author":"Curtin","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.radonc.2017.09.043_b0010","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1093\/mutage\/geh025","article-title":"Endogenous DNA damage in humans: a review of quantitative data","volume":"19","author":"De Bont","year":"2004","journal-title":"Mutagenesis"},{"key":"10.1016\/j.radonc.2017.09.043_b0015","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/ncb2897","article-title":"Causes and consequences of replication stress","volume":"16","author":"Zeman","year":"2014","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.radonc.2017.09.043_b0020","doi-asserted-by":"crossref","first-page":"7749","DOI":"10.1038\/sj.onc.1210880","article-title":"ATM and the Mre11 complex combine to recognize and signal DNA double-strand breaks","volume":"26","author":"Lavin","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.radonc.2017.09.043_b0025","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1126\/science.1083430","article-title":"Sensing DNA damage through ATRIP recognition of RPA-ssDNA complexes","volume":"300","author":"Zou","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.radonc.2017.09.043_b0030","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1126\/science.1065521","article-title":"ATR and ATRIP: partners in checkpoint signaling","volume":"294","author":"Cortez","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.radonc.2017.09.043_b0035","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1007\/PL00008656","article-title":"Characterization of a Saccharomyces cerevisiae homologue of Schizosaccharomyces pombe Chk1 involved in DNA-damage-induced M-phase arrest","volume":"262","author":"Liu","year":"2000","journal-title":"Mol General Genetics: MGG."},{"key":"10.1016\/j.radonc.2017.09.043_b0040","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1158\/1078-0432.CCR-06-2793","article-title":"Targeting checkpoint kinase 1 in cancer therapeutics","volume":"13","author":"Tse","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.radonc.2017.09.043_b0045","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1038\/onc.2008.17","article-title":"The checkpoint kinases Chk1 and Chk2 regulate the functional associations between hBRCA2 and Rad51 in response to DNA damage","volume":"27","author":"Bahassi","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.radonc.2017.09.043_b0050","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1158\/1078-0432.CCR-09-1029","article-title":"New insights into checkpoint kinase 1 in the DNA damage response signaling network","volume":"16","author":"Dai","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.radonc.2017.09.043_b0055","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.molmed.2010.10.009","article-title":"Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics","volume":"17","author":"Ma","year":"2011","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.radonc.2017.09.043_b0060","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1038\/sj.onc.1207394","article-title":"Cdc25A phosphatase: combinatorial phosphorylation, ubiquitylation and proteolysis","volume":"23","author":"Busino","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.radonc.2017.09.043_b0065","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1126\/science.277.5331.1501","article-title":"Mitotic and G2 checkpoint control: regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216","volume":"277","author":"Peng","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.radonc.2017.09.043_b0070","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S1535-6108(03)00048-5","article-title":"Chk1 regulates the S phase checkpoint by coupling the physiological turnover and ionizing radiation-induced accelerated proteolysis of Cdc25A","volume":"3","author":"Sorensen","year":"2003","journal-title":"Cancer Cell"},{"key":"10.1016\/j.radonc.2017.09.043_b0075","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1002\/j.1460-2075.1995.tb07180.x","article-title":"Regulation of the human WEE1Hu CDK tyrosine 15-kinase during the cell cycle","volume":"14","author":"Watanabe","year":"1995","journal-title":"EMBO J"},{"key":"10.1016\/j.radonc.2017.09.043_b0080","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1093\/emboj\/16.3.545","article-title":"Chk1 is a wee1 kinase in the G2 DNA damage checkpoint inhibiting cdc2 by Y15 phosphorylation","volume":"16","author":"O'Connell","year":"1997","journal-title":"EMBO J"},{"key":"10.1016\/j.radonc.2017.09.043_b0085","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1091\/mbc.12.3.551","article-title":"Positive regulation of Wee1 by Chk1 and 14-3-3 proteins","volume":"12","author":"Lee","year":"2001","journal-title":"Mol Biol Cell"},{"key":"10.1016\/j.radonc.2017.09.043_b0090","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/B978-0-12-380888-2.00003-0","article-title":"The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer","volume":"108","author":"Smith","year":"2010","journal-title":"Adv Cancer Res"},{"key":"10.1016\/j.radonc.2017.09.043_b0095","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1073\/pnas.0611584104","article-title":"Cross-talk between Chk1 and Chk2 in double-mutant thymocytes","volume":"104","author":"Zaugg","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.radonc.2017.09.043_b0100","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1093\/jmcb\/mju045","article-title":"CHK2 kinase in the DNA damage response and beyond","volume":"6","author":"Zannini","year":"2014","journal-title":"J Mol Cell Biol"},{"key":"10.1016\/j.radonc.2017.09.043_b0105","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1083\/jcb.200104099","article-title":"Activation of mammalian Chk1 during DNA replication arrest: a role for Chk1 in the intra-S phase checkpoint monitoring replication origin firing","volume":"154","author":"Feijoo","year":"2001","journal-title":"J Cell Biol"},{"key":"10.1016\/j.radonc.2017.09.043_b0110","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.dnarep.2015.04.026","article-title":"Preventing replication fork collapse to maintain genome integrity","volume":"32","author":"Cortez","year":"2015","journal-title":"DNA Repair"},{"key":"10.1016\/j.radonc.2017.09.043_b0115","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.yexcr.2014.09.019","article-title":"Replication stress and cancer: it takes two to tango","volume":"329","author":"Lecona","year":"2014","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.radonc.2017.09.043_b0120","doi-asserted-by":"crossref","first-page":"7139","DOI":"10.1158\/0008-5472.CAN-04-1289","article-title":"ATR affecting cell radiosensitivity is dependent on homologous recombination repair but independent of nonhomologous end joining","volume":"64","author":"Wang","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.radonc.2017.09.043_b0125","doi-asserted-by":"crossref","first-page":"e91222","DOI":"10.1371\/journal.pone.0091222","article-title":"ATR suppresses endogenous DNA damage and allows completion of homologous recombination repair","volume":"9","author":"Brown","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.radonc.2017.09.043_b0130","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/ncb1212","article-title":"The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair","volume":"7","author":"Sorensen","year":"2005","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.radonc.2017.09.043_b0135","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1093\/nar\/gkr748","article-title":"A dual role of BRCA1 in two distinct homologous recombination mediated repair in response to replication arrest","volume":"40","author":"Feng","year":"2012","journal-title":"Nucl Acids Res"},{"key":"10.1016\/j.radonc.2017.09.043_b0140","doi-asserted-by":"crossref","first-page":"7139","DOI":"10.1158\/0008-5472.CAN-04-1289","article-title":"ATR affecting cell radiosensitivity is dependent on homologous recombination repair but independent of nonhomologous end joining","volume":"64","author":"Wang","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.radonc.2017.09.043_b0145","doi-asserted-by":"crossref","first-page":"3098","DOI":"10.1128\/MCB.02357-06","article-title":"Chk1-mediated phosphorylation of FANCE is required for the Fanconi anemia\/BRCA pathway","volume":"27","author":"Wang","year":"2007","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.radonc.2017.09.043_b0150","doi-asserted-by":"crossref","first-page":"8775","DOI":"10.1158\/0008-5472.CAN-09-2312","article-title":"Fanconi anemia complementation group FANCD2 protein serine 331 phosphorylation is important for fanconi anemia pathway function and BRCA2 interaction","volume":"69","author":"Zhi","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.radonc.2017.09.043_b0155","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1101\/gad.13.20.2633","article-title":"XRCC3 promotes homology-directed repair of DNA damage in mammalian cells","volume":"13","author":"Pierce","year":"1999","journal-title":"Genes Dev"},{"key":"10.1016\/j.radonc.2017.09.043_b0160","doi-asserted-by":"crossref","first-page":"5166","DOI":"10.1128\/MCB.19.7.5166","article-title":"Sister chromatid exchanges are mediated by homologous recombination in vertebrate cells","volume":"19","author":"Sonoda","year":"1999","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.radonc.2017.09.043_b0165","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1101\/gad.14.4.397","article-title":"ATR disruption leads to chromosomal fragmentation and early embryonic lethality","volume":"14","author":"Brown","year":"2000","journal-title":"Genes Dev"},{"key":"10.1016\/j.radonc.2017.09.043_b0170","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0960-9822(00)00447-4","article-title":"Targeted disruption of the cell-cycle checkpoint gene ATR leads to early embryonic lethality in mice","volume":"10","author":"de Klein","year":"2000","journal-title":"Curr Biol: CB"},{"key":"10.1016\/j.radonc.2017.09.043_b0175","doi-asserted-by":"crossref","first-page":"7859","DOI":"10.1021\/jm500415t","article-title":"Development of synthetic lethality anticancer therapeutics","volume":"57","author":"Fang","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.radonc.2017.09.043_b0180","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ctrv.2013.03.002","article-title":"Targeting ATR in DNA damage response and cancer therapeutics","volume":"40","author":"Fokas","year":"2014","journal-title":"Cancer Treatment Rev"},{"key":"10.1016\/j.radonc.2017.09.043_b0185","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1172\/JCI58765","article-title":"Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models","volume":"122","author":"Ma","year":"2012","journal-title":"J Clin Investig"},{"key":"10.1016\/j.radonc.2017.09.043_b0190","doi-asserted-by":"crossref","first-page":"4321","DOI":"10.4161\/cc.10.24.18661","article-title":"Selective radiosensitization of p53 mutant pancreatic cancer cells by combined inhibition of Chk1 and PARP1","volume":"10","author":"Vance","year":"2011","journal-title":"Cell Cycle"},{"key":"10.1016\/j.radonc.2017.09.043_b0195","doi-asserted-by":"crossref","DOI":"10.3390\/cancers9050041","article-title":"Targeting the ATR-CHK1 Axis in Cancer Therapy","volume":"9","author":"Rundle","year":"2017","journal-title":"Cancers"},{"key":"10.1016\/j.radonc.2017.09.043_b0200","first-page":"791","article-title":"Enhancement of cisplatin-induced cytotoxicity by 7-hydroxystaurosporine (UCN-01), a new G2-checkpoint inhibitor","volume":"2","author":"Bunch","year":"1996","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.radonc.2017.09.043_b0205","first-page":"3248","article-title":"Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human alpha1-acid glycoprotein","volume":"58","author":"Fuse","year":"1998","journal-title":"Cancer Res"},{"key":"10.1016\/j.radonc.2017.09.043_b0210","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1023\/A:1007512832006","article-title":"Physiological modeling of altered pharmacokinetics of a novel anticancer drug, UCN-01 (7-hydroxystaurosporine), caused by slow dissociation of UCN-01 from human alpha1-acid glycoprotein","volume":"17","author":"Fuse","year":"2000","journal-title":"Pharmaceut Res"},{"key":"10.1016\/j.radonc.2017.09.043_b0215","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1124\/mi.11.2.11","article-title":"CHK1 inhibitors in combination chemotherapy: thinking beyond the cell cycle","volume":"11","author":"Dent","year":"2011","journal-title":"Mol Intervent"},{"key":"10.1016\/j.radonc.2017.09.043_b0220","doi-asserted-by":"crossref","first-page":"5600","DOI":"10.1074\/jbc.275.8.5600","article-title":"The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01","volume":"275","author":"Graves","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1016\/j.radonc.2017.09.043_b0225","doi-asserted-by":"crossref","first-page":"104","DOI":"10.4161\/cc.6.1.3699","article-title":"Pharmacological abrogation of S-phase checkpoint enhances the anti-tumor activity of gemcitabine in vivo","volume":"6","author":"Matthews","year":"2007","journal-title":"Cell Cycle"},{"key":"10.1016\/j.radonc.2017.09.043_b0230","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1158\/1535-7163.MCT-06-0371","article-title":"Cell cycle phenotype-based optimization of G2-abrogating peptides yields CBP501 with a unique mechanism of action at the G2 checkpoint","volume":"6","author":"Sha","year":"2007","journal-title":"Mol Cancer Therapeut"},{"key":"10.1016\/j.radonc.2017.09.043_b0235","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1158\/1078-0432.CCR-10-2345","article-title":"Phase I studies of CBP501, a G2 checkpoint abrogator, as monotherapy and in combination with cisplatin in patients with advanced solid tumors","volume":"17","author":"Shapiro","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.radonc.2017.09.043_b0240","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.lungcan.2014.06.008","article-title":"Randomized phase II trial of pemetrexed\/cisplatin with or without CBP501 in patients with advanced malignant pleural mesothelioma","volume":"85","author":"Krug","year":"2014","journal-title":"Lung cancer."},{"key":"10.1016\/j.radonc.2017.09.043_b0245","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1158\/1535-7163.MCT-08-0492","article-title":"AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies","volume":"7","author":"Zabludoff","year":"2008","journal-title":"Mol Cancer Therapeut"},{"key":"10.1016\/j.radonc.2017.09.043_b0250","doi-asserted-by":"crossref","first-page":"4972","DOI":"10.1158\/0008-5472.CAN-09-3573","article-title":"Mechanism of radiosensitization by the Chk1\/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair","volume":"70","author":"Morgan","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.radonc.2017.09.043_b0255","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1186\/1471-2407-14-570","article-title":"Chk1 inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers","volume":"14","author":"Bryant","year":"2014","journal-title":"BMC cancer."},{"key":"10.1016\/j.radonc.2017.09.043_b0260","doi-asserted-by":"crossref","first-page":"3706","DOI":"10.1158\/1078-0432.CCR-10-3082","article-title":"Assessment of chk1 phosphorylation as a pharmacodynamic biomarker of chk1 inhibition","volume":"17","author":"Parsels","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.radonc.2017.09.043_b0265","doi-asserted-by":"crossref","first-page":"3683","DOI":"10.1158\/0008-5472.CAN-13-0110","article-title":"ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status","volume":"73","author":"Huntoon","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.radonc.2017.09.043_b0270","doi-asserted-by":"crossref","first-page":"5130","DOI":"10.1021\/jm300025r","article-title":"Discovery of checkpoint kinase inhibitor (S)-5-(3-fluorophenyl)-N-(piperidin-3-yl)-3-ureidothiophene-2-carboxamide (AZD7762) by structure-based design and optimization of thiophenecarboxamide ureas","volume":"55","author":"Oza","year":"2012","journal-title":"J Med Chem"},{"key":"10.1016\/j.radonc.2017.09.043_b0275","doi-asserted-by":"crossref","first-page":"995","DOI":"10.4161\/cc.9.5.10935","article-title":"Chk1 inhibition after replicative stress activates a double strand break response mediated by ATM and DNA-dependent protein kinase","volume":"9","author":"McNeely","year":"2010","journal-title":"Cell Cycle"},{"key":"10.1016\/j.radonc.2017.09.043_b0280","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1124\/mol.105.012716","article-title":"Gemcitabine-induced activation of checkpoint signaling pathways that affect tumor cell survival","volume":"68","author":"Karnitz","year":"2005","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.radonc.2017.09.043_b0285","doi-asserted-by":"crossref","first-page":"897","DOI":"10.3892\/mmr.2012.999","article-title":"The Chk1 inhibitor AZD7762 sensitises p53 mutant breast cancer cells to radiation in vitro and in vivo","volume":"6","author":"Ma","year":"2012","journal-title":"Molecular medicine reports."},{"key":"10.1016\/j.radonc.2017.09.043_b0290","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1158\/1535-7163.MCT-13-0157","article-title":"Chk1\/2 inhibition overcomes the cisplatin resistance of head and neck cancer cells secondary to the loss of functional p53","volume":"12","author":"Gadhikar","year":"2013","journal-title":"Mol Cancer Therapeut"},{"key":"10.1016\/j.radonc.2017.09.043_b0295","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1158\/1535-7163.MCT-11-0949","article-title":"The checkpoint kinase inhibitor AZD7762 potentiates chemotherapy-induced apoptosis of p53-mutated multiple myeloma cells","volume":"11","author":"Landau","year":"2012","journal-title":"Mol Cancer Therapeut"},{"key":"10.1016\/j.radonc.2017.09.043_b0300","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1158\/1078-0432.CCR-09-3277","article-title":"In vitro and in vivo radiation sensitization of human tumor cells by a novel checkpoint kinase inhibitor, AZD7762","volume":"16","author":"Mitchell","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.radonc.2017.09.043_b0305","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1124\/mol.112.078907","article-title":"Poly(ADP-ribose) polymerase 1 modulates the lethality of CHK1 inhibitors in mammary tumors","volume":"82","author":"Tang","year":"2012","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.radonc.2017.09.043_b0310","first-page":"5843","article-title":"Abrogation of the Chk1-mediated G(2) checkpoint pathway potentiates temozolomide-induced toxicity in a p53-independent manner in human glioblastoma cells","volume":"61","author":"Hirose","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.radonc.2017.09.043_b0315","doi-asserted-by":"crossref","first-page":"6635","DOI":"10.1158\/0008-5472.CAN-04-0841","article-title":"Potentiation of cytotoxicity of topoisomerase i poison by concurrent and sequential treatment with the checkpoint inhibitor UCN-01 involves disparate mechanisms resulting in either p53-independent clonogenic suppression or p53-dependent mitotic catastrophe","volume":"64","author":"Tse","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.radonc.2017.09.043_b0320","doi-asserted-by":"crossref","first-page":"6149","DOI":"10.1038\/onc.2010.343","article-title":"Status of p53 in human cancer cells does not predict efficacy of CHK1 kinase inhibitors combined with chemotherapeutic agents","volume":"29","author":"Zenvirt","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.radonc.2017.09.043_b0325","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1038\/onc.2014.276","article-title":"ATR inhibition preferentially targets homologous recombination-deficient tumor cells","volume":"34","author":"Krajewska","year":"2015","journal-title":"Oncogene"},{"key":"10.1016\/j.radonc.2017.09.043_b0330","doi-asserted-by":"crossref","first-page":"34688","DOI":"10.18632\/oncotarget.9156","article-title":"Targeting radioresistant breast cancer cells by single agent CHK1 inhibitor via enhancing replication stress","volume":"7","author":"Zhang","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.radonc.2017.09.043_b0335","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s00280-014-2380-5","article-title":"Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors","volume":"73","author":"Sausville","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.radonc.2017.09.043_b0340","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s00280-013-2234-6","article-title":"Phase I, dose-escalation study of AZD7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumours","volume":"72","author":"Seto","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.radonc.2017.09.043_b0345","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s10637-013-0036-7","article-title":"Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor","volume":"32","author":"King","year":"2014","journal-title":"Investig New Drugs"},{"key":"10.1016\/j.radonc.2017.09.043_b0350","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1007\/s10637-014-0114-5","article-title":"Preclinical analyses and phase I evaluation of LY2603618 administered in combination with pemetrexed and cisplatin in patients with advanced cancer","volume":"32","author":"Calvo","year":"2014","journal-title":"Investig New Drugs"},{"key":"10.1016\/j.radonc.2017.09.043_b0355","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s10637-012-9815-9","article-title":"Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg\/m(2) every 21 days in patients with cancer","volume":"31","author":"Weiss","year":"2013","journal-title":"Investig New Drugs"},{"key":"10.1016\/j.radonc.2017.09.043_b0360","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1097\/CAD.0000000000000278","article-title":"Phase I study of LY2603618, a CHK1 inhibitor, in combination with gemcitabine in Japanese patients with solid tumors","volume":"26","author":"Doi","year":"2015","journal-title":"Anti-cancer Drugs"},{"key":"10.1016\/j.radonc.2017.09.043_b0365","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1159\/000448621","article-title":"Phase I Study of CHK1 Inhibitor LY2603618 in Combination with Gemcitabine in Patients with Solid Tumors","volume":"91","author":"Calvo","year":"2016","journal-title":"Oncology."},{"key":"10.1016\/j.radonc.2017.09.043_b0370","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s10637-016-0368-1","article-title":"Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer","volume":"34","author":"Scagliotti","year":"2016","journal-title":"Investig New Drugs"},{"key":"10.1016\/j.radonc.2017.09.043_b0375","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1158\/1535-7163.MCT-10-0928","article-title":"Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screening","volume":"10","author":"Guzi","year":"2011","journal-title":"Mol Cancer Therapeut"},{"key":"10.1016\/j.radonc.2017.09.043_b0380","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1158\/1535-7163.MCT-11-0406","article-title":"Preclinical development of the novel Chk1 inhibitor SCH900776 in combination with DNA-damaging agents and antimetabolites","volume":"11","author":"Montano","year":"2012","journal-title":"Mol Cancer Therapeut"},{"key":"10.1016\/j.radonc.2017.09.043_b0385","doi-asserted-by":"crossref","first-page":"4412","DOI":"10.1158\/1078-0432.CCR-12-3748","article-title":"Sensitization of pancreatic cancer to chemoradiation by the Chk1 inhibitor MK8776","volume":"19","author":"Engelke","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.radonc.2017.09.043_b0390","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1186\/1471-2407-13-604","article-title":"Sensitization of human cancer cells to gemcitabine by the Chk1 inhibitor MK-8776: cell cycle perturbation and impact of administration schedule in vitro and in vivo","volume":"13","author":"Montano","year":"2013","journal-title":"BMC Cancer"},{"key":"10.1016\/j.radonc.2017.09.043_b0395","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.lungcan.2013.09.010","article-title":"CHK1 levels correlate with sensitization to pemetrexed by CHK1 inhibitors in non-small cell lung cancer cells","volume":"82","author":"Grabauskiene","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1016\/j.radonc.2017.09.043_b0400","doi-asserted-by":"crossref","first-page":"5364","DOI":"10.1158\/1078-0432.CCR-12-0961","article-title":"Effects of selective checkpoint kinase 1 inhibition on cytarabine cytotoxicity in acute myelogenous leukemia cells in vitro","volume":"18","author":"Schenk","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.radonc.2017.09.043_b0405","doi-asserted-by":"crossref","unstructured":"Bridges KA, Chen X, Liu H, Rock C, Buchholz TA, Shumway SD, et al. MK-8776, a novel chk1 kinase inhibitor, radiosensitizes p53-defective human tumor cells. Oncotarget; 2016.","DOI":"10.18632\/oncotarget.12311"},{"key":"10.1016\/j.radonc.2017.09.043_b0410","doi-asserted-by":"crossref","first-page":"6723","DOI":"10.1158\/1078-0432.CCR-12-2442","article-title":"Phase I and pharmacologic trial of cytosine arabinoside with the selective checkpoint 1 inhibitor Sch 900776 in refractory acute leukemias","volume":"18","author":"Karp","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.radonc.2017.09.043_b0415","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1200\/JCO.2014.57.5027","article-title":"Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors","volume":"33","author":"Daud","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2017.09.043_b0420","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1158\/1535-7163.MCT-07-2391","article-title":"Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1","volume":"7","author":"Blasina","year":"2008","journal-title":"Mol Cancer Therapeut"},{"key":"10.1016\/j.radonc.2017.09.043_b0425","doi-asserted-by":"crossref","first-page":"4630","DOI":"10.1158\/1078-0432.CCR-08-3272","article-title":"PF-00477736 mediates checkpoint kinase 1 signaling pathway and potentiates docetaxel-induced efficacy in xenografts","volume":"15","author":"Zhang","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.radonc.2017.09.043_b0430","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1007\/s11684-013-0270-6","article-title":"Combined gemcitabine and CHK1 inhibitor treatment induces apoptosis resistance in cancer stem cell-like cells enriched with tumor spheroids from a non-small cell lung cancer cell line","volume":"7","author":"Fang","year":"2013","journal-title":"Front Med"},{"key":"10.1016\/j.radonc.2017.09.043_b0435","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1158\/1078-0432.CCR-14-0048","article-title":"Gemcitabine and CHK1 inhibition potentiate EGFR-directed radioimmunotherapy against pancreatic ductal adenocarcinoma","volume":"20","author":"Al-Ejeh","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.radonc.2017.09.043_b0440","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.radonc.2013.06.035","article-title":"HPV-positive HNSCC cell lines but not primary human fibroblasts are radiosensitized by the inhibition of Chk1","volume":"108","author":"Busch","year":"2013","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2017.09.043_b0445","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1158\/1535-7163.MCT-14-1037","article-title":"LY2606368 Causes replication catastrophe and antitumor effects through CHK1-dependent mechanisms","volume":"14","author":"King","year":"2015","journal-title":"Mol Cancer Therapeut"},{"key":"10.1016\/j.radonc.2017.09.043_b0450","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1200\/JCO.2015.64.5788","article-title":"Phase I study of LY2606368, a checkpoint kinase 1 inhibitor, in patients with advanced cancer","volume":"34","author":"Hong","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2017.09.043_b0455","doi-asserted-by":"crossref","first-page":"3118","DOI":"10.1021\/jm048989d","article-title":"1-(5-Chloro-2-alkoxyphenyl)-3-(5-cyanopyrazin-2-yl)ureas [correction of cyanopyrazi] as potent and selective inhibitors of Chk1 kinase: synthesis, preliminary SAR, and biological activities","volume":"48","author":"Wang","year":"2005","journal-title":"J Med Chem"},{"key":"10.1016\/j.radonc.2017.09.043_b0460","doi-asserted-by":"crossref","first-page":"5650","DOI":"10.1158\/1078-0432.CCR-12-1322","article-title":"CCT244747 is a novel potent and selective CHK1 inhibitor with oral efficacy alone and in combination with genotoxic anticancer drugs","volume":"18","author":"Walton","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.radonc.2017.09.043_b0465","doi-asserted-by":"crossref","first-page":"10229","DOI":"10.1021\/jm3012933","article-title":"Discovery of 3-alkoxyamino-5-(pyridin-2-ylamino)pyrazine-2-carbonitriles as selective, orally bioavailable CHK1 inhibitors","volume":"55","author":"Lainchbury","year":"2012","journal-title":"J Med Chem"},{"key":"10.1016\/j.radonc.2017.09.043_b0470","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1158\/1535-7163.MCT-15-0998","article-title":"CHK1 inhibition radiosensitizes head and neck cancers to paclitaxel-based chemoradiotherapy","volume":"15","author":"Barker","year":"2016","journal-title":"Mol Cancer Therapeut"},{"key":"10.1016\/j.radonc.2017.09.043_b0475","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1158\/1078-0432.CCR-06-1424","article-title":"CHIR-124, a novel potent inhibitor of Chk1, potentiates the cytotoxicity of topoisomerase I poisons in vitro and in vivo","volume":"13","author":"Tse","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.radonc.2017.09.043_b0480","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.4161\/cc.8.8.8203","article-title":"Radiosensitization by Chir-124, a selective CHK1 inhibitor: effects of p53 and cell cycle checkpoints","volume":"8","author":"Tao","year":"2009","journal-title":"Cell Cycle"},{"key":"10.1016\/j.radonc.2017.09.043_b0485","doi-asserted-by":"crossref","first-page":"19629","DOI":"10.1073\/pnas.1117544108","article-title":"Role of checkpoint kinase 1 (Chk1) in the mechanisms of resistance to histone deacetylase inhibitors","volume":"108","author":"Lee","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.radonc.2017.09.043_b0490","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1158\/1535-7163.MCT-13-0404","article-title":"Identification of preferred chemotherapeutics for combining with a CHK1 inhibitor","volume":"12","author":"Xiao","year":"2013","journal-title":"Mol Cancer Therapeut"},{"key":"10.1016\/j.radonc.2017.09.043_b0495","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1479-5876-7-43","article-title":"Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer","volume":"7","author":"Azorsa","year":"2009","journal-title":"J Transl Med"},{"key":"10.1016\/j.radonc.2017.09.043_b0500","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1158\/1535-7163.MCT-08-0662","article-title":"Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells","volume":"8","author":"Parsels","year":"2009","journal-title":"Mol Cancer Therap"},{"key":"10.1016\/j.radonc.2017.09.043_b0505","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1158\/1535-7163.MCT-09-0938","article-title":"The preclinical pharmacology and therapeutic activity of the novel CHK1 inhibitor SAR-020106","volume":"9","author":"Walton","year":"2010","journal-title":"Mol Cancer Therap"},{"key":"10.1016\/j.radonc.2017.09.043_b0510","doi-asserted-by":"crossref","first-page":"8328","DOI":"10.1021\/jm2007326","article-title":"Structure-guided evolution of potent and selective CHK1 inhibitors through scaffold morphing","volume":"54","author":"Reader","year":"2011","journal-title":"J Med Chem"},{"key":"10.1016\/j.radonc.2017.09.043_b0515","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.ijrobp.2012.08.006","article-title":"Targeted radiosensitization by the Chk1 inhibitor SAR-020106","volume":"85","author":"Borst","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2017.09.043_b0520","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.radonc.2013.05.036","article-title":"Optimising measles virus-guided radiovirotherapy with external beam radiotherapy and specific checkpoint kinase 1 inhibition","volume":"108","author":"Touchefeu","year":"2013","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2017.09.043_b0525","first-page":"566","article-title":"An indolocarbazole inhibitor of human checkpoint kinase (Chk1) abrogates cell cycle arrest caused by DNA damage","volume":"60","author":"Jackson","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.radonc.2017.09.043_b0530","doi-asserted-by":"crossref","first-page":"6547","DOI":"10.1158\/1078-0432.CCR-06-1178","article-title":"Schedule-dependent synergy between the heat shock protein 90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin and doxorubicin restores apoptosis to p53-mutant lymphoma cell lines","volume":"12","author":"Robles","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.radonc.2017.09.043_b0535","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.bcp.2016.01.017","article-title":"Chk1 inhibitor synergizes quinacrine mediated apoptosis in breast cancer cells by compromising the base excision repair cascade","volume":"105","author":"Preet","year":"2016","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.radonc.2017.09.043_b0540","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.1158\/0008-5472.CAN-14-3347","article-title":"CHK1 inhibition synergizes with gemcitabine initially by destabilizing the DNA replication apparatus","volume":"75","author":"Koh","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.radonc.2017.09.043_b0545","doi-asserted-by":"crossref","first-page":"35797","DOI":"10.18632\/oncotarget.5929","article-title":"Identification of novel, in vivo active Chk1 inhibitors utilizing structure guided drug design","volume":"6","author":"Massey","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.radonc.2017.09.043_b0550","doi-asserted-by":"crossref","first-page":"5678","DOI":"10.1093\/nar\/gkp593","article-title":"Inhibition of ATR protein kinase activity by schisandrin B in DNA damage response","volume":"37","author":"Nishida","year":"2009","journal-title":"Nucl Acids Res"},{"key":"10.1016\/j.radonc.2017.09.043_b0555","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1254\/jphs.13048FP","article-title":"Differential effect of schisandrin B stereoisomers on ATR-mediated DNA damage checkpoint signaling","volume":"122","author":"Tatewaki","year":"2013","journal-title":"J Pharmacol Sci"},{"key":"10.1016\/j.radonc.2017.09.043_b0560","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.pharmthera.2014.12.001","article-title":"ATM and ATR as therapeutic targets in cancer","volume":"149","author":"Weber","year":"2015","journal-title":"Pharmacol Therap"},{"key":"10.1016\/j.radonc.2017.09.043_b0565","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/bjc.2011.243","article-title":"Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines","volume":"105","author":"Peasland","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1016\/j.radonc.2017.09.043_b0570","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/nsmb.2076","article-title":"A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations","volume":"18","author":"Toledo","year":"2011","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.radonc.2017.09.043_b0575","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1021\/jm101520v","article-title":"Discovery of 9-(6-aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo[h][1,6]naphthyridin-2(1H)-one (Torin2) as a potent, selective, and orally available mammalian target of rapamycin (mTOR) inhibitor for treatment of cancer","volume":"54","author":"Liu","year":"2011","journal-title":"J Med Chem"},{"key":"10.1016\/j.radonc.2017.09.043_b0580","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1021\/jm101488z","article-title":"Discovery of potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase as potential anticancer agents","volume":"54","author":"Charrier","year":"2011","journal-title":"J Med Chem"},{"key":"10.1016\/j.radonc.2017.09.043_b0585","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.4161\/cbt.21093","article-title":"The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy","volume":"13","author":"Prevo","year":"2012","journal-title":"Cancer Biol Therap"},{"key":"10.1016\/j.radonc.2017.09.043_b0590","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/bjc.2012.265","article-title":"Targeting radiation-resistant hypoxic tumour cells through ATR inhibition","volume":"107","author":"Pires","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1016\/j.radonc.2017.09.043_b0595","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s00411-013-0486-5","article-title":"Inhibition of ATR kinase with the selective inhibitor VE-821 results in radiosensitization of cells of promyelocytic leukaemia (HL-60)","volume":"52","author":"Vavrova","year":"2013","journal-title":"Radiat Environ Biophys"},{"key":"10.1016\/j.radonc.2017.09.043_b0600","doi-asserted-by":"crossref","first-page":"12007","DOI":"10.3390\/ijms150712007","article-title":"Radiosensitization of human leukemic HL-60 cells by ATR kinase inhibitor (VE-821): phosphoproteomic analysis","volume":"15","author":"Salovska","year":"2014","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.radonc.2017.09.043_b0605","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s13014-015-0464-y","article-title":"VE-821, an ATR inhibitor, causes radiosensitization in human tumor cells irradiated with high LET radiation","volume":"10","author":"Fujisawa","year":"2015","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.radonc.2017.09.043_b0610","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/nchembio.573","article-title":"Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR","volume":"7","author":"Reaper","year":"2011","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.radonc.2017.09.043_b0615","doi-asserted-by":"crossref","first-page":"e0125482","DOI":"10.1371\/journal.pone.0125482","article-title":"A synthetic lethal screen identifies DNA repair pathways that sensitize cancer cells to combined ATR inhibition and cisplatin treatments","volume":"10","author":"Mohni","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.radonc.2017.09.043_b0620","doi-asserted-by":"crossref","first-page":"6968","DOI":"10.1158\/0008-5472.CAN-13-3369","article-title":"ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase i inhibitors by disabling DNA replication initiation and fork elongation responses","volume":"74","author":"Josse","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.radonc.2017.09.043_b0625","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.molonc.2014.09.012","article-title":"Development of pharmacodynamic biomarkers for ATR inhibitors","volume":"9","author":"Chen","year":"2015","journal-title":"Mol Oncol"},{"key":"10.1016\/j.radonc.2017.09.043_b0630","doi-asserted-by":"crossref","first-page":"e441","DOI":"10.1038\/cddis.2012.181","article-title":"Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation","volume":"3","author":"Fokas","year":"2012","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.radonc.2017.09.043_b0635","doi-asserted-by":"crossref","first-page":"5674","DOI":"10.18632\/oncotarget.2158","article-title":"Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970","volume":"5","author":"Hall","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.radonc.2017.09.043_b0640","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.radonc.2016.10.023","article-title":"Preclinical testing of an Atr inhibitor demonstrates improved response to standard therapies for esophageal cancer","volume":"121","author":"Leszczynska","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2017.09.043_b0645","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1021\/jm301859s","article-title":"Discovery of 4-{4-[(3R)-3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-y l}-1H-indole (AZ20): a potent and selective inhibitor of ATR protein kinase with monotherapy in vivo antitumor activity","volume":"56","author":"Foote","year":"2013","journal-title":"J Med Chem"},{"key":"10.1016\/j.radonc.2017.09.043_b0650","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1158\/1538-7445.AM2013-2348","article-title":"Abstract 2348: discovery of AZD6738, a potent and selective inhibitor with the potential to test the clinical efficacy of ATR kinase inhibition in cancer patients","volume":"73","author":"Jones","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.radonc.2017.09.043_b0655","doi-asserted-by":"crossref","first-page":"44289","DOI":"10.18632\/oncotarget.6247","article-title":"The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo","volume":"6","author":"Vendetti","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.radonc.2017.09.043_b0660","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1158\/1535-7163.MCT-16-0239","article-title":"Radiosensitization by the ATR Inhibitor AZD6738 through Generation of Acentric Micronuclei","volume":"16","author":"Dillon","year":"2017","journal-title":"Mol Cancer Therap"},{"key":"10.1016\/j.radonc.2017.09.043_b0665","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1182\/blood-2015-05-644872","article-title":"ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells","volume":"127","author":"Kwok","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.radonc.2017.09.043_b0670","doi-asserted-by":"crossref","first-page":"14349","DOI":"10.1074\/jbc.M411890200","article-title":"The role of checkpoint kinase 1 in sensitivity to topoisomerase I poisons","volume":"280","author":"Flatten","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.radonc.2017.09.043_b0675","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/bcp.12139","article-title":"The cancer therapeutic potential of Chk1 inhibitors: how mechanistic studies impact on clinical trial design","volume":"76","author":"Thompson","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.radonc.2017.09.043_b0680","doi-asserted-by":"crossref","first-page":"26553","DOI":"10.1074\/jbc.M202040200","article-title":"Abrogation of the S phase DNA damage checkpoint results in S phase progression or premature mitosis depending on the concentration of 7-hydroxystaurosporine and the kinetics of Cdc25C activation","volume":"277","author":"Kohn","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.radonc.2017.09.043_b0685","first-page":"4029","article-title":"Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53 function","volume":"57","author":"Shao","year":"1997","journal-title":"Cancer Res"},{"key":"10.1016\/j.radonc.2017.09.043_b0690","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/S0006-2952(99)00258-0","article-title":"Comparison of the efficacy of 7-hydroxystaurosporine (UCN-01) and other staurosporine analogs to abrogate cisplatin-induced cell cycle arrest in human breast cancer cell lines","volume":"58","author":"Lee","year":"1999","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.radonc.2017.09.043_b0695","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1124\/jpet.109.154997","article-title":"Cellular inhibition of checkpoint kinase 2 (Chk2) and potentiation of camptothecins and radiation by the novel Chk2 inhibitor PV1019 [7-nitro-1H-indole-2-carboxylic acid {4-[1-(guanidinohydrazone)-ethyl]-phenyl}-amide]","volume":"331","author":"Jobson","year":"2009","journal-title":"J Pharmacol Exp Therapeut"},{"key":"10.1016\/j.radonc.2017.09.043_b0700","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.tranon.2017.04.002","article-title":"MK-8776, a novel Chk1 inhibitor, exhibits an improved radiosensitizing effect compared to UCN-01 by exacerbating radiation-induced aberrant mitosis","volume":"10","author":"Suzuki","year":"2017","journal-title":"Transl Oncol"},{"key":"10.1016\/j.radonc.2017.09.043_b0705","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1084\/jem.20112147","article-title":"An extra allele of Chk1 limits oncogene-induced replicative stress and promotes transformation","volume":"209","author":"Lopez-Contreras","year":"2012","journal-title":"J Exp Med"},{"key":"10.1016\/j.radonc.2017.09.043_b0710","doi-asserted-by":"crossref","first-page":"9693","DOI":"10.1158\/0008-5472.CAN-10-2286","article-title":"Combining ATR suppression with oncogenic Ras synergistically increases genomic instability, causing synthetic lethality or tumorigenesis in a dosage-dependent manner","volume":"70","author":"Gilad","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.radonc.2017.09.043_b0715","doi-asserted-by":"crossref","first-page":"6574","DOI":"10.1158\/0008-5472.CAN-06-3545","article-title":"The E2F-regulated gene Chk1 is highly expressed in triple-negative estrogen receptor \/progesterone receptor \/HER-2 breast carcinomas","volume":"67","author":"Verlinden","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.radonc.2017.09.043_b0720","doi-asserted-by":"crossref","first-page":"3336","DOI":"10.1073\/pnas.1012351108","article-title":"RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma","volume":"108","author":"Cole","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.radonc.2017.09.043_b0725","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1038\/onc.2014.248","article-title":"CHK1 overexpression in T-cell acute lymphoblastic leukemia is essential for proliferation and survival by preventing excessive replication stress","volume":"34","author":"Sarmento","year":"2015","journal-title":"Oncogene"},{"key":"10.1016\/j.radonc.2017.09.043_b0730","doi-asserted-by":"crossref","first-page":"8652","DOI":"10.1158\/0008-5472.CAN-09-0939","article-title":"Constitutive activation of the DNA damage signaling pathway in acute myeloid leukemia with complex karyotype: potential importance for checkpoint targeting therapy","volume":"69","author":"Cavelier","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.radonc.2017.09.043_b0735","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1172\/JCI61380","article-title":"CHK1 targets spleen tyrosine kinase (L) for proteolysis in hepatocellular carcinoma","volume":"122","author":"Hong","year":"2012","journal-title":"J Clin Investig"},{"key":"10.1016\/j.radonc.2017.09.043_b0740","doi-asserted-by":"crossref","first-page":"7067","DOI":"10.1158\/1078-0432.CCR-11-1198","article-title":"Therapeutic implications for the induced levels of Chk1 in Myc-expressing cancer cells","volume":"17","author":"Hoglund","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.radonc.2017.09.043_b0745","doi-asserted-by":"crossref","first-page":"604","DOI":"10.4161\/cc.2.6.503","article-title":"Characterization of the 5'flanking region of the human Chk1 gene: identification of E2F1 functional sites","volume":"2","author":"Carrassa","year":"2003","journal-title":"Cell Cycle"},{"key":"10.1016\/j.radonc.2017.09.043_b0750","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/nature03482","article-title":"DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis","volume":"434","author":"Bartkova","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.radonc.2017.09.043_b0755","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/nature03485","article-title":"Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions","volume":"434","author":"Gorgoulis","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.radonc.2017.09.043_b0760","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1038\/nsmb.2189","article-title":"Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors","volume":"18","author":"Murga","year":"2011","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.radonc.2017.09.043_b0765","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1038\/onc.2011.358","article-title":"Efficacy of CHK inhibitors as single agents in MYC-driven lymphoma cells","volume":"31","author":"Ferrao","year":"2012","journal-title":"Oncogene"},{"key":"10.1016\/j.radonc.2017.09.043_b0770","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1038\/onc.2012.72","article-title":"A potent Chk1 inhibitor is selectively cytotoxic in melanomas with high levels of replicative stress","volume":"32","author":"Brooks","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.radonc.2017.09.043_b0775","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1172\/JCI58928","article-title":"Oncogenic stress sensitizes murine cancers to hypomorphic suppression of ATR","volume":"122","author":"Schoppy","year":"2012","journal-title":"J Clin Investig"},{"key":"10.1016\/j.radonc.2017.09.043_b0780","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1038\/ng.420","article-title":"A mouse model of ATR-Seckel shows embryonic replicative stress and accelerated aging","volume":"41","author":"Murga","year":"2009","journal-title":"Nat Genet"},{"key":"10.1016\/j.radonc.2017.09.043_b0785","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/ng.441","article-title":"Tissue regenerative delays and synthetic lethality in adult mice after combined deletion of Atr and Trp53","volume":"41","author":"Ruzankina","year":"2009","journal-title":"Nat Genet"},{"key":"10.1016\/j.radonc.2017.09.043_b0790","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1002\/pmic.201500172","article-title":"ATR inhibition rewires cellular signaling networks induced by replication stress","volume":"16","author":"Wagner","year":"2016","journal-title":"Proteomics"},{"key":"10.1016\/j.radonc.2017.09.043_b0795","doi-asserted-by":"crossref","first-page":"827","DOI":"10.3109\/00498254.2014.900589","article-title":"Disposition and metabolism of LY2603618, a Chk-1 inhibitor following intravenous administration in patients with advanced and\/or metastatic solid tumors","volume":"44","author":"Wickremsinhe","year":"2014","journal-title":"Xenobiotica; The Fate of Foreign Compounds in Biological Systems"},{"key":"10.1016\/j.radonc.2017.09.043_b0800","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1158\/1078-0432.664.11.2","article-title":"A phase I and pharmacokinetic study of short infusions of UCN-01 in patients with refractory solid tumors","volume":"11","author":"Dees","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.radonc.2017.09.043_b0805","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1200\/JCO.2001.19.8.2319","article-title":"Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms","volume":"19","author":"Sausville","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2017.09.043_b0810","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/cncr.20313","article-title":"Time to disease progression to evaluate a novel protein kinase C inhibitor, UCN-01, in renal cell carcinoma","volume":"101","author":"Rini","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2017.09.043_b0815","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s10637-010-9562-8","article-title":"A phase II study of cell cycle inhibitor UCN-01 in patients with metastatic melanoma: a California Cancer Consortium trial","volume":"30","author":"Li","year":"2012","journal-title":"Investig New Drugs"},{"key":"10.1016\/j.radonc.2017.09.043_b0820","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1146\/annurev.genet.41.110306.130308","article-title":"Cell cycle regulation of DNA replication","volume":"41","author":"Sclafani","year":"2007","journal-title":"Ann Rev Genet"},{"key":"10.1016\/j.radonc.2017.09.043_b0825","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.semcancer.2016.01.001","article-title":"DNA replication and cancer: From dysfunctional replication origin activities to therapeutic opportunities","volume":"37\u201338","author":"Boyer","year":"2016","journal-title":"Sem Cancer Biol"},{"key":"10.1016\/j.radonc.2017.09.043_b0830","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1083\/jcb.200404092","article-title":"Deregulation of cyclin E in human cells interferes with prereplication complex assembly","volume":"165","author":"Ekholm-Reed","year":"2004","journal-title":"J Cell Biol"},{"key":"10.1016\/j.radonc.2017.09.043_b0835","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.1038\/onc.2012.387","article-title":"Increased replication initiation and conflicts with transcription underlie Cyclin E-induced replication stress","volume":"32","author":"Jones","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.radonc.2017.09.043_b0840","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/febs.13574","article-title":"Targeting DNA repair, DNA metabolism and replication stress as anti-cancer strategies","volume":"283","author":"Puigvert","year":"2016","journal-title":"FEBS J"},{"key":"10.1016\/j.radonc.2017.09.043_b0845","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.cell.2013.10.043","article-title":"ATR prohibits replication catastrophe by preventing global exhaustion of RPA","volume":"155","author":"Toledo","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.radonc.2017.09.043_b0850","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1159\/000080596","article-title":"A role for the MutL homologue MLH2 in controlling heteroduplex formation and in regulating between two different crossover pathways in budding yeast","volume":"107","author":"Abdullah","year":"2004","journal-title":"Cytogenet Genome Res"},{"key":"10.1016\/j.radonc.2017.09.043_b0855","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.1128\/MCB.25.9.3553-3562.2005","article-title":"Inhibition of human Chk1 causes increased initiation of DNA replication, phosphorylation of ATR targets, and DNA breakage","volume":"25","author":"Syljuasen","year":"2005","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.radonc.2017.09.043_b0860","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1042\/BJ20112100","article-title":"Replication fork dynamics and the DNA damage response","volume":"443","author":"Jones","year":"2012","journal-title":"Biochem J"},{"key":"10.1016\/j.radonc.2017.09.043_b0865","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1128\/MCB.26.8.3319-3326.2006","article-title":"Chk1 requirement for high global rates of replication fork progression during normal vertebrate S phase","volume":"26","author":"Petermann","year":"2006","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.radonc.2017.09.043_b0870","doi-asserted-by":"crossref","first-page":"16090","DOI":"10.1073\/pnas.1005031107","article-title":"Chk1 promotes replication fork progression by controlling replication initiation","volume":"107","author":"Petermann","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.radonc.2017.09.043_b0875","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.4161\/cc.8.7.8040","article-title":"Claspin and Chk1 regulate replication fork stability by different mechanisms","volume":"8","author":"Scorah","year":"2009","journal-title":"Cell Cycle"},{"key":"10.1016\/j.radonc.2017.09.043_b0880","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/379088a0","article-title":"Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours","volume":"379","author":"Graeber","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.radonc.2017.09.043_b0885","doi-asserted-by":"crossref","first-page":"6556","DOI":"10.1158\/0008-5472.CAN-04-1520","article-title":"Inhibition of ATR leads to increased sensitivity to hypoxia\/reoxygenation","volume":"64","author":"Hammond","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.radonc.2017.09.043_b0890","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.mrfmmm.2003.08.017","article-title":"Comparison of hypoxia-induced replication arrest with hydroxyurea and aphidicolin-induced arrest","volume":"532","author":"Hammond","year":"2003","journal-title":"Mutat Res"},{"key":"10.1016\/j.radonc.2017.09.043_b0895","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1128\/MCB.22.6.1834-1843.2002","article-title":"Hypoxia links ATR and p53 through replication arrest","volume":"22","author":"Hammond","year":"2002","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.radonc.2017.09.043_b0900","doi-asserted-by":"crossref","first-page":"5624","DOI":"10.1158\/1078-0432.CCR-10-0286","article-title":"Targeting hypoxic cells through the DNA damage response","volume":"16","author":"Olcina","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.radonc.2017.09.043_b0905","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1021\/cb4001537","article-title":"CH-01 is a hypoxia-activated prodrug that sensitizes cells to hypoxia\/reoxygenation through inhibition of Chk1 and Aurora A","volume":"8","author":"Cazares-Korner","year":"2013","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.radonc.2017.09.043_b0910","doi-asserted-by":"crossref","first-page":"8504","DOI":"10.1128\/MCB.24.19.8504-8518.2004","article-title":"Down-regulation of Rad51 and decreased homologous recombination in hypoxic cancer cells","volume":"24","author":"Bindra","year":"2004","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.radonc.2017.09.043_b0915","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1158\/0008-5472.CAN-07-5472","article-title":"Chronic hypoxia decreases synthesis of homologous recombination proteins to offset chemoresistance and radioresistance","volume":"68","author":"Chan","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.radonc.2017.09.043_b0920","doi-asserted-by":"crossref","first-page":"8045","DOI":"10.1158\/0008-5472.CAN-10-2352","article-title":"Contextual synthetic lethality of cancer cell kill based on the tumor microenvironment","volume":"70","author":"Chan","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.radonc.2017.09.043_b0925","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.dnarep.2015.04.030","article-title":"Multifaceted control of DNA repair pathways by the hypoxic tumor microenvironment","volume":"32","author":"Scanlon","year":"2015","journal-title":"DNA Repair"},{"key":"10.1016\/j.radonc.2017.09.043_b0930","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1016\/j.molcel.2017.03.005","article-title":"Ribonucleotide reductase requires subunit switching in hypoxia to maintain DNA replication","volume":"66","author":"Foskolou","year":"2017","journal-title":"Mol Cell"},{"key":"10.1016\/j.radonc.2017.09.043_b0935","doi-asserted-by":"crossref","first-page":"788","DOI":"10.4161\/cbt.12.9.17673","article-title":"Chk1 inhibition and Wee1 inhibition combine synergistically to impede cellular proliferation","volume":"12","author":"Davies","year":"2011","journal-title":"Cancer Biol Therap"},{"key":"10.1016\/j.radonc.2017.09.043_b0940","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.4161\/cc.20899","article-title":"Combined inhibition of Chk1 and Wee1: in vitro synergistic effect translates to tumor growth inhibition in vivo","volume":"11","author":"Carrassa","year":"2012","journal-title":"Cell Cycle"},{"key":"10.1016\/j.radonc.2017.09.043_b0945","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1475-2867-12-45","article-title":"Unique functions of CHK1 and WEE1 underlie synergistic anti-tumor activity upon pharmacologic inhibition","volume":"12","author":"Guertin","year":"2012","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.radonc.2017.09.043_b0950","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1158\/0008-5472.CAN-12-2669","article-title":"Combination therapy targeting the Chk1 and Wee1 kinases shows therapeutic efficacy in neuroblastoma","volume":"73","author":"Russell","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.radonc.2017.09.043_b0955","doi-asserted-by":"crossref","first-page":"3394","DOI":"10.18632\/oncotarget.2583","article-title":"Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma","volume":"6","author":"Chila","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.radonc.2017.09.043_b0960","doi-asserted-by":"crossref","first-page":"10546","DOI":"10.18632\/oncotarget.2508","article-title":"Pharmacological targeting the ATR-CHK1-WEE1 axis involves balancing cell growth stimulation and apoptosis","volume":"5","author":"Mak","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.radonc.2017.09.043_b0965","doi-asserted-by":"crossref","first-page":"35755","DOI":"10.18632\/oncotarget.5928","article-title":"Chemogenetic profiling identifies RAD17 as synthetically lethal with checkpoint kinase inhibition","volume":"6","author":"Shen","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.radonc.2017.09.043_b0970","doi-asserted-by":"crossref","first-page":"4226","DOI":"10.1128\/MCB.00412-12","article-title":"Cyclin-dependent kinase suppression by WEE1 kinase protects the genome through control of replication initiation and nucleotide consumption","volume":"32","author":"Beck","year":"2012","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.radonc.2017.09.043_b0975","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1083\/jcb.201101047","article-title":"Wee1 controls genomic stability during replication by regulating the Mus81-Eme1 endonuclease","volume":"194","author":"Dominguez-Kelly","year":"2011","journal-title":"J Cell Biol"},{"key":"10.1016\/j.radonc.2017.09.043_b0980","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1186\/s12885-015-1474-8","article-title":"Combined inhibition of the cell cycle related proteins Wee1 and Chk1\/2 induces synergistic anti-cancer effect in melanoma","volume":"15","author":"Magnussen","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.radonc.2017.09.043_b0985","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1158\/1541-7786.MCR-14-0240","article-title":"A synthetic lethal screen reveals enhanced sensitivity to ATR inhibitor treatment in mantle cell lymphoma with ATM loss-of-function","volume":"13","author":"Menezes","year":"2015","journal-title":"Mol Cancer Res: MCR"},{"key":"10.1016\/j.radonc.2017.09.043_b0990","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1158\/0008-5472.CAN-13-3229","article-title":"ATR pathway inhibition is synthetically lethal in cancer cells with ERCC1 deficiency","volume":"74","author":"Mohni","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.radonc.2017.09.043_b0995","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.celrep.2015.12.032","article-title":"Cancer-specific synthetic lethality between ATR and CHK1 kinase activities","volume":"14","author":"Sanjiv","year":"2016","journal-title":"Cell Reports"},{"key":"10.1016\/j.radonc.2017.09.043_b1000","doi-asserted-by":"crossref","first-page":"6019","DOI":"10.1242\/jcs.01400","article-title":"Characterization of a novel ATR-dependent, Chk1-independent, intra-S-phase checkpoint that suppresses initiation of replication in Xenopus","volume":"117","author":"Luciani","year":"2004","journal-title":"J Cell Sci"},{"key":"10.1016\/j.radonc.2017.09.043_b1005","doi-asserted-by":"crossref","first-page":"6461","DOI":"10.18632\/oncotarget.14120","article-title":"Activation of ATR-Chk1 pathway facilitates EBV-mediated transformation of primary tonsillar B-cells","volume":"8","author":"Mordasini","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.radonc.2017.09.043_b1010","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.molcel.2015.07.029","article-title":"Distinct but concerted roles of ATR, DNA-PK, and Chk1 in countering replication stress during S Phase","volume":"59","author":"Buisson","year":"2015","journal-title":"Mol Cell"},{"key":"10.1016\/j.radonc.2017.09.043_b1015","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1158\/1535-7163.MCT-10-0781","article-title":"Context dependence of checkpoint kinase 1 as a therapeutic target for pancreatic cancers deficient in the BRCA2 tumor suppressor","volume":"10","author":"Hattori","year":"2011","journal-title":"Mol Cancer Therap"},{"key":"10.1016\/j.radonc.2017.09.043_b1020","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1476-4598-8-24","article-title":"CHK1 inhibition as a strategy for targeting Fanconi Anemia (FA) DNA repair pathway deficient tumors","volume":"8","author":"Chen","year":"2009","journal-title":"Mol Cancer"},{"key":"10.1016\/j.radonc.2017.09.043_b1025","doi-asserted-by":"crossref","first-page":"e57098","DOI":"10.1371\/journal.pone.0057098","article-title":"Ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase inhibition is synthetically lethal in XRCC1 deficient ovarian cancer cells","volume":"8","author":"Sultana","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.radonc.2017.09.043_b1030","doi-asserted-by":"crossref","first-page":"7080","DOI":"10.18632\/oncotarget.6857","article-title":"A synthetic lethal screen identifies ATR-inhibition as a novel therapeutic approach for POLD1-deficient cancers","volume":"7","author":"Hocke","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.radonc.2017.09.043_b1035","doi-asserted-by":"crossref","first-page":"8109","DOI":"10.1158\/0008-5472.CAN-06-0140","article-title":"Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition","volume":"66","author":"McCabe","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.radonc.2017.09.043_b1040","doi-asserted-by":"crossref","first-page":"458","DOI":"10.4161\/cbt.24424","article-title":"PARP and CHK inhibitors interact to cause DNA damage and cell death in mammary carcinoma cells","volume":"14","author":"Booth","year":"2013","journal-title":"Cancer Biol Therap"},{"key":"10.1016\/j.radonc.2017.09.043_b1045","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.2005070","article-title":"Targeting poly(ADP-ribose) polymerase and the c-Myb-regulated DNA damage response pathway in castration-resistant prostate cancer","volume":"7","author":"Li","year":"2014","journal-title":"Sci Signal"},{"key":"10.1016\/j.radonc.2017.09.043_b1050","doi-asserted-by":"crossref","first-page":"5189","DOI":"10.1182\/blood-2011-02-339432","article-title":"Cytokinetically quiescent (G0\/G1) human multiple myeloma cells are susceptible to simultaneous inhibition of Chk1 and MEK1\/2","volume":"118","author":"Pei","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.radonc.2017.09.043_b1055","unstructured":"Pei X-Y, Dai Y, Chen S, Bodie W, Kramer L, Dent P, et al. The MEK1\/2 inhibitor AZD6244 (ARRY-142886) interacts synergistically with the novel Chk1 inhibitor AZD7762 to induce apoptosis in human multiple myeloma cells. Cancer Res 2014;68:LB-103-LB-."},{"key":"10.1016\/j.radonc.2017.09.043_b1060","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.1158\/1538-7445.AM2016-3711","article-title":"Abstract 3711: Pre-clinical combinations of ATR and PARP inhibitors: Defining target patient populations and dose schedule","volume":"76","author":"Pollard","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.radonc.2017.09.043_b1065","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.1182\/blood-2006-09-047076","article-title":"Statins synergistically potentiate 7-hydroxystaurosporine (UCN-01) lethality in human leukemia and myeloma cells by disrupting Ras farnesylation and activation","volume":"109","author":"Dai","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.radonc.2017.09.043_b1070","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1182\/blood-2008-05-159392","article-title":"Interruption of the Ras\/MEK\/ERK signaling cascade enhances Chk1 inhibitor-induced DNA damage in vitro and in vivo in human multiple myeloma cells","volume":"112","author":"Dai","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.radonc.2017.09.043_b1075","doi-asserted-by":"crossref","first-page":"215","DOI":"10.4161\/cbt.12.3.16218","article-title":"Simultaneous exposure of transformed cells to SRC family inhibitors and CHK1 inhibitors causes cell death","volume":"12","author":"Mitchell","year":"2011","journal-title":"Cancer Biol Therap"},{"key":"10.1016\/j.radonc.2017.09.043_b1080","doi-asserted-by":"crossref","first-page":"379","DOI":"10.4161\/cbt.19240","article-title":"Enhancing CHK1 inhibitor lethality in glioblastoma","volume":"13","author":"Tang","year":"2012","journal-title":"Cancer Biol Therap"},{"key":"10.1016\/j.radonc.2017.09.043_b1085","first-page":"5106","article-title":"Pharmacological inhibitors of the mitogen-activated protein kinase (MAPK) kinase\/MAPK cascade interact synergistically with UCN-01 to induce mitochondrial dysfunction and apoptosis in human leukemia cells","volume":"61","author":"Dai","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.radonc.2017.09.043_b1090","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1182\/blood-2007-04-083204","article-title":"MEK1\/2 inhibitors potentiate UCN-01 lethality in human multiple myeloma cells through a Bim-dependent mechanism","volume":"110","author":"Pei","year":"2007","journal-title":"Blood"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814017326312?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814017326312?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T17:35:30Z","timestamp":1659634530000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814017326312"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":218,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["S0167814017326312"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2017.09.043","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ATR\/CHK1 inhibitors and cancer therapy","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2017.09.043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}